Ribociclib Treatment and ReX Technology for Metastatic Breast Cancer
This study is looking at how well a device called ReX helps people take their ribociclib (a medication for breast cancer) and how long they continue using it. The ReX device is a portable dispenser that helps you take your solid oral medications. Researchers want to see if using ReX helps people take their ribociclib as prescribed and for a longer time, compared to those not using ReX. You may be able to join if you are at least 18 years old, have HR+ HER2- metastatic breast cancer, and started ribociclib treatment within the last 60 days. The study aims to enroll 200 participants. The study status is currently unclear.
- Study design
- This is an open-label, controlled study, meaning both you and your doctors will know what treatment you are receiving. It plans to enroll 200 participants.
- What's involved
- You would use the ReX device to dispense and monitor your solid oral medication therapy for up to 12 months. You will also complete electronic patient-reported outcome questions.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 12 months to measure the use of the ReX platform.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
At a glance
Conditions
Where it's being run
4 sites across 4 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Outcome MeasureReX Platform Study GroupUp to 12 months
Numerical variables will be tabulated using mean, standard deviation, minimum, median, maximum and number of observations. Categorical variables will be tabulated using number of observations and percentages. Two interim analyses are planned for this study: Interim analysis no. 1 will summarize 50 reviewed patient charts from the control group (completed as for January 2024) Interim analysis no. 2 will summarize about 25-30 participants from the ReX group, who used ReX for at least 1 month, and will compare them to control group (planned for April 2024).